Literature DB >> 21952064

The prevalence and economic impact of low-enrolling clinical studies at an academic medical center.

Darlene R Kitterman1, Steven K Cheng, David M Dilts, Eric S Orwoll.   

Abstract

PURPOSE: The authors assessed the prevalence and associated economic impact of low-enrolling clinical studies at a single academic medical center.
METHOD: The authors examined all clinical studies receiving institutional review board (IRB) review between FY2006 and FY2009 at Oregon Health & Science University (OHSU) for recruitment performance and analyzed them by type of IRB review (full-board, exempt, expedited), funding mechanism, and academic unit. A low-enrolling study included those with zero or one participant at the time of study termination. The authors calculated the costs associated with IRB review, financial setup, contract negotiation, and department study start-up activities and the total economic impact on OHSU of low-enrolling studies for FY2009.
RESULTS: A total of 837 clinical studies were terminated during the study period, 260 (31.1%) of which were low-enrolling. A greater proportion of low-enrolling studies were government funded than industry funded (P=.006). The authors found significant differences among the various academic units with respect to percentages of low-enrolling studies (from 10% to 67%). The uncompensated economic impact of low-enrolling studies was conservatively estimated to be nearly $1 million for FY2009.
CONCLUSIONS: A substantial proportion of clinical studies incurred high institutional and departmental expense but resulted in little scientific benefit. Although a certain percentage of low-enrolling studies can be expected in any research organization, the overall number of such studies must be managed to reduce the aggregate costs of conducting research and to maximize research opportunities. Effective, proactive interventions are needed to address the prevalence and impact of low enrollment.

Entities:  

Mesh:

Year:  2011        PMID: 21952064      PMCID: PMC3203249          DOI: 10.1097/ACM.0b013e3182306440

Source DB:  PubMed          Journal:  Acad Med        ISSN: 1040-2446            Impact factor:   6.893


  11 in total

1.  Obstacles facing translational research in academic medical centers.

Authors:  J S Pober; C S Neuhauser; J M Pober
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

2.  US cancer trials may go the way of the Oldsmobile.

Authors:  David Dilts
Journal:  Nat Med       Date:  2010-06       Impact factor: 53.440

3.  Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.

Authors:  Anneke T Schroen; Gina R Petroni; Hongkun Wang; Robert Gray; Xiaofei F Wang; Walter Cronin; Daniel J Sargent; Jacqueline Benedetti; Donald L Wickerham; Benjamin Djulbegovic; Craig L Slingluff
Journal:  Clin Trials       Date:  2010-07-01       Impact factor: 2.486

4.  Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials.

Authors:  Steven K Cheng; Mary S Dietrich; David M Dilts
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

5.  Applying results of randomised trials to clinical practice: impact of losses before randomisation.

Authors:  M E Charlson; R I Horwitz
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-10

6.  Reengineering the national clinical and translational research enterprise: the strategic plan of the National Clinical and Translational Science Awards Consortium.

Authors:  Steven E Reis; Lars Berglund; Gordon R Bernard; Robert M Califf; Garret A Fitzgerald; Peter C Johnson
Journal:  Acad Med       Date:  2010-03       Impact factor: 6.893

7.  Linking scientific discovery and better health for the nation: the first three years of the NIH's Clinical and Translational Science Awards.

Authors:  Robert M Califf; Lars Berglund
Journal:  Acad Med       Date:  2010-03       Impact factor: 6.893

8.  A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.

Authors:  Steven K Cheng; Mary S Dietrich; David M Dilts
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

9.  Phase III clinical trial development: a process of chutes and ladders.

Authors:  David M Dilts; Steven K Cheng; Joshua S Crites; Alan B Sandler; James H Doroshow
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

10.  Enrollment in clinical trials: institutional factors affecting enrollment in the cardiac arrhythmia suppression trial (CAST).

Authors:  S Shea; J T Bigger; J Campion; J L Fleiss; L M Rolnitzky; E Schron; L Gorkin; K Handshaw; M R Kinney; M Branyon
Journal:  Control Clin Trials       Date:  1992-12
View more
  48 in total

1.  Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.

Authors:  Caroline S Bennette; Scott D Ramsey; Cara L McDermott; Josh J Carlson; Anirban Basu; David L Veenstra
Journal:  J Natl Cancer Inst       Date:  2015-12-29       Impact factor: 13.506

2.  StudySearch: a web-based application for posting and searching clinical research studies.

Authors:  Blair Gonsenhauser; Rose Hallarn; Daniel Carpenter; Michael F Para; Carson R Reider
Journal:  J Investig Med       Date:  2016-01-29       Impact factor: 2.895

3.  Highly effective cystic fibrosis clinical research teams: critical success factors.

Authors:  George Z Retsch-Bogart; Jill M Van Dalfsen; Bruce C Marshall; Cynthia George; Joseph M Pilewski; Eugene C Nelson; Christopher H Goss; Bonnie W Ramsey
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

4.  Evaluating protocol lifecycle time intervals in HIV/AIDS clinical trials.

Authors:  Scott R Rosas; Jeffrey T Schouten; Dennis Dixon; Suresh Varghese; Marie T Cope; Joe Marci; Jonathan M Kagan
Journal:  Clin Trials       Date:  2014-06-30       Impact factor: 2.486

Review 5.  Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.

Authors:  Holly A Massett; Grace Mishkin; Larry Rubinstein; S Percy Ivy; Andrea Denicoff; Elizabeth Godwin; Kate DiPiazza; Jennifer Bolognese; James A Zwiebel; Jeffrey S Abrams
Journal:  Clin Cancer Res       Date:  2016-07-11       Impact factor: 12.531

6.  Commentary: Improving participant recruitment in clinical and translational research.

Authors:  Nariman Nasser; Deborah Grady; C William Balke
Journal:  Acad Med       Date:  2011-11       Impact factor: 6.893

7.  Recruitment strategies in two reproductive medicine network infertility trials.

Authors:  Rebecca S Usadi; Michael P Diamond; Richard S Legro; William D Schlaff; Karl R Hansen; Peter Casson; Gregory Christman; G Wright Bates; Valerie Baker; Aimee Seungdamrong; Mitchell P Rosen; Scott Lucidi; Tracey Thomas; Hao Huang; Nanette Santoro; Esther Eisenberg; Heping Zhang; Ruben Alvero
Journal:  Contemp Clin Trials       Date:  2015-09-18       Impact factor: 2.226

8.  Accrual Index: A Real-Time Measure of the Timeliness of Clinical Study Enrollment.

Authors:  Lauren Corregano; Katelyn Bastert; Joel Correa da Rosa; Rhonda G Kost
Journal:  Clin Transl Sci       Date:  2015-11-17       Impact factor: 4.689

9.  Recruitment of black subjects for a natural history study of intracerebral hemorrhage.

Authors:  Dorothy F Edwards; Ravi Menon; Ali Fokar; Christopher Gibbons; Jeffrey Wing; Brisa Sanchez; Chelsea S Kidwell
Journal:  J Health Care Poor Underserved       Date:  2013-02

10.  Developing future clinician scientists while supporting a research infrastructure.

Authors:  Maija Holsti; Kathleen M Adelgais; Leah Willis; Kammy Jacobsen; Edward B Clark; Carrie L Byington
Journal:  Clin Transl Sci       Date:  2013-04       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.